Evaluation of metabolic labeling for comparative proteomics in breast cancer cells.

Protein expression patterns in the cytosol of MCF-7 cells resistant to adriamycin and to adriamycin/verapamil were compared to that of the parental MCF-7 cell line and to each other using metabolic labeling and two-dimensional gel electrophoresis. Growing the parental MCF-7 cell line in 13C6-arginine- and 13C6-lysine-enriched medium resulted in C-terminal labeling of all tryptic peptides. The culture media was optimized for the incorporation of these labeled amino acids under conditions that also supported cell growth. Protein abundances were found to be distinctive in MCF-7 cells resistant to adriamycin and those selected for resistance to both adriamycin and verapamil.

[1]  F. Regnier,et al.  Minimizing resolution of isotopically coded peptides in comparative proteomics. , 2002, Journal of proteome research.

[2]  A. Tulpule,et al.  Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. , 1986, The Journal of biological chemistry.

[3]  F. Regnier,et al.  Global internal standard technology for comparative proteomics. , 2002, Journal of chromatography. A.

[4]  K. Hemminki,et al.  Re: markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. , 2000, Journal of the National Cancer Institute.

[5]  C. Swanson,et al.  Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. , 1993, British Journal of Cancer.

[6]  A. English,et al.  Quantitative analysis of the yeast proteome by incorporation of isotopically labeled leucine. , 2002, Journal of proteome research.

[7]  Y. Hathout,et al.  Differential protein expression in the cytosol fraction of an MCF-7 breast cancer cell line selected for resistance toward melphalan. , 2002, Journal of proteome research.

[8]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Y. Hathout,et al.  Proteomic phenotyping: metastatic and invasive breast cancer. , 2004, Cancer letters.

[10]  D. Scudiero,et al.  Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. , 1998, Journal of the National Cancer Institute.

[11]  A. Multani,et al.  Multidrug-resistant MCF-7 cells: an identity crisis? , 2002, Journal of the National Cancer Institute.